The French Acute Myeloid Leukemia Intergroup analyzed the response to dasatinib in high-risk CBF AML patients(including high white blood cell count, KIT and/orFLT3mutations, and a less than 3-log MRD reduction) presenting less than 3-log MRD reduction before the second high-dose cytarabine (HiDAC) consolidation course or with molecular recurrence with no sibling available received dasatinib as a 1-year post-consolidation maintenance treatment. This evidence concerns the gene KIT and acute myeloid leukemia.